Výsledky vyhledávání - "Garcia Ribas, Ignacio"

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC)

Autor: Cutsem, Eric, Eefsen, Rikke Lovendahl, Sebastian Ochsenreither, Zvirbule, Zanete, Ivanauskas, Audrius, Arnold, Dirk, Baltruskeviciene, Edita, Pfeiffer, Per, Yachnin, Jeffrey, Garcia Carbonero, Rocio, Greil, Richard, Jungels, Christiane, Poulsen, Laurids, Awada, Ahmad, Garcia Ribas, Ignacio, Losic, Nedjad, Collignon, Joelle

Publikováno v: Van Cutsem, E, Eefsen, R L, Ochsenreither, S, Zvirbule, Z, Ivanauskas, A, Arnold, D, Baltruskeviciene, E, Pfeiffer, P, Yachnin, J, Garcia Carbonero, R, Greil, R, Jungels, C, Poulsen, L, Awada, A, Garcia Ribas, I, Losic, N & Collignon, J 2022, ' Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC). ', Journal of Clinical Oncology, vol. 40, no. Suppl. 16, pp. 4141 . < https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4141 >
Web of Science

4141 Background: Interleukin-1 Receptor Accessory Protein (IL1RAP) is expressed on cancer and stromal cells in PDAC. The IL-1 pathway is active in the pancreatic tumor microenvironment and upregulated in response to chemotherapy. IL1RAP interacts wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bab54ad0b1145eb4e3bda2e7e8f52859
https://vbn.aau.dk/da/publications/41e10015-43bf-4647-9aaa-eb976c04bada

Zobrazit plný text záznamu

Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.:Journal of Clinical Oncology

Autor: Awada, Ahmad, Ochsenreither, Sebastian, Eefsen, Rikke Loevendahl, Arnold, Dirk, Yachnin, Jeffrey, Pfeiffer, Per, Jungels, Christiane, Greil, Richard, Poulsen, Laurids, Van Cutsem, Eric, Thorsson, Lars, Svedman, Christer, Garcia-Ribas, Ignacio, Collignon, Joelle

Publikováno v: Awada, A, Ochsenreither, S, Eefsen, R L, Arnold, D, Yachnin, J, Pfeiffer, P, Jungels, C, Greil, R, Poulsen, L, Van Cutsem, E, Thorsson, L, Svedman, C, Garcia-Ribas, I & Collignon, J 2021, ' Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. Journal of Clinical Oncology ', Journal of Clinical Oncology, vol. 39, no. Suppl. 15, e16228 . https://doi.org/10.1200/JCO.2021.39.15_suppl.e16228
Awada, A, Ochsenreither, S, Eefsen, R L, Arnold, D, Yachnin, J, Pfeiffer, P, Jungels, C, Greil, R, Poulsen, L, Van Cutsem, E, Thorsson, L, Svedman, C, Garcia-Ribas, I & Collignon, J 2021, ' Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. Journal of Clinical Oncology ', Journal of Clinical Oncology, vol. 39, no. 15. suppl, e16228 . https://doi.org/10.1200/JCO.2021.39.15_suppl.e16228

e16228Background: Interleukin-1 Receptor Accessory Protein (IL1RAP) is expressed on cancer and stromal cells in many solid tumors. CAN04 is a fully humanized IgG1 targeting IL1RAP blocking IL-1α and ? signaling and triggering ADCC. As monotherapy, C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7ca218eaa878e85447af075f89d15432
https://portal.findresearcher.sdu.dk/da/publications/92cc03ef-9e7d-4dec-bd62-d28a792af0f6

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání